LINEAGE CELL THERAPEUTICS INLCTX
ASignal's systematic analysis rates LCTX as Bearish.
Reflects the latest available analysis · analyzed Oct 11, 2026
The case on LCTX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- Low debt-to-equity ratio (0.04x)
- High cash position with $50.83M cash
- Current ratio of 6.61x indicates strong liquidity
- MACD histogram is positive and rising
- Negative revenue growth (-61.30%)
- Negative profit, operating, and gross margins
- Negative return on equity (-60.06%) and return on assets (-17.04%)
- Forward P/E of -7.23x and EV/EBITDA of -8.07x indicate unprofitability
- High PEG ratio of 10.64x suggests overvaluation relative to growth
See the full verdict on LCTX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes LCTX
Most investors never get a second opinion, let alone several. ASignal runs LCTX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.